
## INTERIM MAINTENANCE II: HIGH RISK ALL

This therapy is for all patients with High Risk B-ALL (post-Induction)

Interim Maintenance II begins on Day 57 of DI or when ANC ≥ 750/µL and platelets ≥ 75000/µL, whichever occurs later. This course lasts 8 weeks (56 days) and this Therapy Delivery Map is on one (1) page.

**VinCRIStine (VCR)**
-	Route: IV push over 1 minute
-	Dosage: 1.5 mg/m2/dose
-   Dilute with 10ml of 0.9% NaCl, IV infusion at 60ml/h
-	Used on Days 1, 11, 21, 31, & 41 
-	Caution: Maximum dose: 2 mg

**Methotrexate (MTX)**
-	Route: IV push over 2-5 min or IV infusion over 10-15 mins
-	Dosage: starting dose for Interim maintenance II is two-thirds of the maximum tolerated dose attained in Interim Maintenance I. Thereafter, escalate by 50 mg/m2/dose (previous dose must be provided). 
-   Dilute with 0.9% NaCl to a target concentration of < 25 mg/mL, administer via IV infusion over 30 mins
-	Used on Days 1, 11, 21, 31, & 41
-	Caution: dosage is escalated over time 

**Intrathecal Methotrexate (IT MTX)**
-	Route: IT 
-	Dosage: 
    + Age (yrs) 1-1.99, dose 8 mg
    + Age (yrs) 2-2.99, dose 10 mg
    + Age (yrs) 3-8.99, dose 12 mg
    + Age (yrs) ≥9, dose 15 mg
    + Used on Days 1 and 31

**L-asparaginase**
-	Route: IM
-	Dosage: 6,000 International Units/m2/dose
-	Used on Day 2, 4, 6, Day 9, 11, 13, Day 22, 24, 26, Day 29, 31, 33 (MWF x 6 doses)
-	Caution: Monitor for one hour after dose for any signs/symptoms of allergic reaction/anaphylaxis
Begin next course (Maintenance) on Day 57 or when blood count parameters are met (whichever occurs later).
